Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53

Table 1

Concentrations for each cytostatic substance and combination applied.

Testing Nutlin concentrations in comparison to Pemetrexed and Cisplatin	Testing Nutlin in combination with Cisplatin in comparison to Pemetrexed and Cisplatin
10nM Cisplatin	10nM Cisplatin
200nM Pemetrexed	200nM Pemetrexed
10nm Cisplatin + 200nM Pemetrexed	10nm Cisplatin + 200nM Pemetrexed
5nM Nutlin	10nm Cisplatin + 5nM Nutlin
10nM Nutlin	10nm Cisplatin + 10nM Nutlin
20nM Nutlin	10nm Cisplatin + 20nM Nutlin
	10nM Nutlin